Sec. 402. Biomedical Advanced Research and Development Authority. 
Sec. 403. Strategic National Stockpile. 
Sec. 404. National Biodefense Science Board. 
TITLE I—STRENGTHENING NA-
TIONAL PREPAREDNESS AND 
RESPONSE 
FOR 
PUBLIC 
HEALTH EMERGENCIES 
SEC. 101. NATIONAL HEALTH SECURITY STRATEGY. 
(a) IN GENERAL.—Section 2802 of the Public Health 
Service Act (42 U.S.C. 300hh–1) is amended— 
(1) in subsection (a)(1), by striking ‘‘2009’’ and 
inserting ‘‘2014’’; and 
(2) in subsection (b)— 
(A) in paragraph (1)(A), by inserting ‘‘, in-
cluding drills and exercises to ensure medical 
surge capacity for events without notice’’ after 
‘‘exercises’’; and 
(B) in paragraph (3)— 
(i) in the matter preceding subpara-
graph (A)— 
(I) by striking ‘‘facilities), and 
trauma care’’ and inserting ‘‘and am-
bulatory care facilities and which may 
include dental health facilities), and 
trauma care, critical care,’’; and 
(II) by inserting ‘‘(including re-
lated availability, accessibility, and co-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00098
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
ordination)’’ after ‘‘public health emer-
gencies’’; 
(ii) in subparagraph (A), by inserting 
‘‘and trauma’’ after ‘‘medical’’; 
(iii) in subparagraph (B), by striking 
‘‘Medical evacuation and fatality manage-
ment’’ and inserting ‘‘Fatality manage-
ment’’; 
(iv) by redesignating subparagraphs 
(C), (D), and (E) as subparagraphs (D), 
(E), and (F), respectively; 
(v) by inserting after subparagraph 
(B), the following the new subparagraph: 
‘‘(C) Coordinated medical triage and evacu-
ation to appropriate medical institutions based 
on patient medical need, taking into account re-
gionalized systems of care.’’; 
(vi) in subparagraph (E), as redesig-
nated by clause (iv), by inserting ‘‘(which 
may include such dental health assets)’’ 
after ‘‘medical assets’’; and 
(vii) by adding at the end the fol-
lowing: 
‘‘(G) Optimizing a coordinated and flexible 
approach to the medical surge capacity of hos-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00099
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
100 
pitals, other health care facilities, critical care, 
trauma care (which may include trauma cen-
ters), and emergency medical systems.’’; 
(C) in paragraph (4)— 
(i) in subparagraph (A), by inserting 
‘‘, including the unique needs and consider-
ations of individuals with disabilities,’’ 
after ‘‘medical needs of at-risk individuals’’; 
and 
(ii) in subparagraph (B), by inserting 
‘‘the’’ before ‘‘purpose of this section’’; and 
(D) by adding at the end the following: 
‘‘(7) COUNTERMEASURES.— 
‘‘(A) Promoting strategic initiatives to ad-
vance countermeasures to diagnose, mitigate, 
prevent, or treat harm from any biological agent 
or toxin, chemical, radiological, or nuclear agent 
or agents, whether naturally occurring, uninten-
tional, or deliberate. 
‘‘(B) For purposes of this paragraph, the 
term ‘countermeasures’ has the same meaning as 
the terms ‘qualified countermeasures’ under sec-
tion 319F–1, ‘qualified pandemic and epidemic 
products’ under section 319F–3, and ‘security 
countermeasures’ under section 319F–2. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00100
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
101 
‘‘(8) MEDICAL AND PUBLIC HEALTH COMMUNITY 
RESILIENCY.—Strengthening the ability of States, 
local communities, and tribal communities to prepare 
for, respond to, and be resilient in the event of public 
health emergencies, whether naturally occurring, un-
intentional, or deliberate by— 
‘‘(A) optimizing alignment and integration 
of medical and public health preparedness and 
response planning and capabilities with and 
into routine daily activities; and 
‘‘(B) promoting familiarity with local med-
ical and public health systems.’’. 
(b) AT-RISK INDIVIDUALS.—Section 2814 of the Public 
Health Service Act (42 U.S.C. 300hh–16) is amended— 
(1) by striking paragraphs (5), (7), and (8); 
(2) 
in 
paragraph 
(4), 
by 
striking 
‘‘2811(b)(3)(B)’’ and inserting ‘‘2802(b)(4)(B)’’; 
(3) by redesignating paragraphs (1) through (4) 
as paragraphs (2) through (5), respectively; 
(4) by inserting before paragraph (2) (as so re-
designated), the following: 
‘‘(1) monitor emerging issues and concerns as 
they relate to medical and public health preparedness 
and response for at-risk individuals in the event of a 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00101
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
102 
public health emergency declared by the Secretary 
under section 319;’’; 
(5) by amending paragraph (2) (as so redesig-
nated) to read as follows: 
‘‘(2) oversee the implementation of the prepared-
ness goals described in section 2802(b) with respect to 
the public health and medical needs of at-risk indi-
viduals in the event of a public health emergency, as 
described in section 2802(b)(4);’’; and 
(6) by inserting after paragraph (6), the fol-
lowing: 
‘‘(7) disseminate and, as appropriate, update 
novel and best practices of outreach to and care of at- 
risk individuals before, during, and following public 
health emergencies in as timely a manner as is prac-
ticable, including from the time a public health threat 
is identified; and 
‘‘(8) ensure that public health and medical infor-
mation distributed by the Department of Health and 
Human Services during a public health emergency is 
delivered in a manner that takes into account the 
range of communication needs of the intended recipi-
ents, including at-risk individuals.’’. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00102
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
103 
SEC. 102. ASSISTANT SECRETARY FOR PREPAREDNESS AND 
RESPONSE. 
(a) IN GENERAL.—Section 2811 of the Public Health 
Service Act (42 U.S.C. 300hh–10) is amended— 
(1) in subsection (b)— 
(A) in paragraph (3), by inserting ‘‘, secu-
rity countermeasures (as defined in section 
319F–2),’’ after ‘‘qualified countermeasures (as 
defined in section 319F–1)’’; 
(B) in paragraph (4), by adding at the end 
the following: 
‘‘(D) POLICY
COORDINATION
AND
STRA-
TEGIC DIRECTION.—Provide integrated policy co-
ordination and strategic direction with respect to 
all matters related to Federal public health and 
medical preparedness and execution and deploy-
ment of the Federal response for public health 
emergencies and incidents covered by the Na-
tional Response Plan developed pursuant to sec-
tion 504(6) of the Homeland Security Act of 
2002, or any successor plan, before, during, and 
following public health emergencies. 
‘‘(E) 
IDENTIFICATION
OF
INEFFICIEN-
CIES.—Identify and minimize gaps, duplication, 
and other inefficiencies in medical and public 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00103
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
104 
health preparedness and response activities and 
the actions necessary to overcome these obstacles. 
‘‘(F) 
COORDINATION
OF
GRANTS
AND 
AGREEMENTS.—Align and coordinate medical 
and public health grants and cooperative agree-
ments as applicable to preparedness and re-
sponse activities authorized under this Act, to the 
extent possible, including program requirements, 
timelines, and measurable goals, and in con-
sultation with the Secretary of Homeland Secu-
rity, to— 
‘‘(i) optimize and streamline medical 
and public health preparedness and re-
sponse capabilities and the ability of local 
communities to respond to public health 
emergencies; and 
‘‘(ii) gather and disseminate best prac-
tices among grant and cooperative agree-
ment recipients, as appropriate. 
‘‘(G) DRILL
AND
OPERATIONAL
EXER-
CISES.—Carry out drills and operational exer-
cises, in consultation with the Department of 
Homeland Security, the Department of Defense, 
the Department of Veterans Affairs, and other 
applicable Federal departments and agencies, as 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00104
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
105 
necessary and appropriate, to identify, inform, 
and address gaps in and policies related to all- 
hazards medical and public health preparedness 
and response, including exercises based on— 
‘‘(i) identified threats for which coun-
termeasures are available and for which no 
countermeasures are available; and 
‘‘(ii) unknown threats for which no 
countermeasures are available. 
‘‘(H) NATIONAL SECURITY PRIORITY.—On a 
periodic basis consult with, as applicable and 
appropriate, the Assistant to the President for 
National Security Affairs, to provide an update 
on, and discuss, medical and public health pre-
paredness and response activities pursuant to 
this Act and the Federal Food, Drug, and Cos-
metic Act, including progress on the develop-
ment, approval, clearance, and licensure of med-
ical countermeasures.’’; and 
(C) by adding at the end the following: 
‘‘(7) COUNTERMEASURES
BUDGET
PLAN.—De-
velop, and update on an annual basis, a coordinated 
5-year budget plan based on the medical counter-
measure priorities described in subsection (d). Each 
such plan shall— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00105
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
106 
‘‘(A) include consideration of the entire 
medical countermeasures enterprise, including— 
‘‘(i) basic research and advanced re-
search and development; 
‘‘(ii) approval, clearance, licensure, 
and authorized uses of products; and 
‘‘(iii) procurement, stockpiling, main-
tenance, and replenishment of all products 
in the Strategic National Stockpile; 
‘‘(B) inform prioritization of resources and 
include measurable outputs and outcomes to 
allow for the tracking of the progress made to-
ward identified priorities; 
‘‘(C) identify medical countermeasure life- 
cycle costs to inform planning, budgeting, and 
anticipated needs within the continuum of the 
medical countermeasure enterprise consistent 
with section 319F–2; and 
‘‘(D) be made available to the appropriate 
committees of Congress upon request.’’; 
(2) by striking subsection (c) and inserting the 
following: 
‘‘(c) FUNCTIONS.—The Assistant Secretary for Pre-
paredness and Response shall— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00106
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
107 
‘‘(1) have lead responsibility within the Depart-
ment of Health and Human Services for emergency 
preparedness and response policy coordination and 
strategic direction; 
‘‘(2) have authority over and responsibility for— 
‘‘(A) the National Disaster Medical System 
pursuant to section 2812; 
‘‘(B) the Hospital Preparedness Cooperative 
Agreement Program pursuant to section 319C–2; 
‘‘(C) the Biomedical Advanced Research 
and Development Authority pursuant to section 
319L; 
‘‘(D) the Medical Reserve Corps pursuant to 
section 2813; 
‘‘(E) the Emergency System for Advance 
Registration of Volunteer Health Professionals 
pursuant to section 319I; and 
‘‘(F) administering grants and related au-
thorities related to trauma care under parts A 
through C of title XII, such authority to be 
transferred by the Secretary from the Adminis-
trator of the Health Resources and Services Ad-
ministration to such Assistant Secretary; 
‘‘(3) exercise the responsibilities and authorities 
of the Secretary with respect to the coordination of— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00107
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
108 
‘‘(A) the Public Health Emergency Pre-
paredness Cooperative Agreement Program pur-
suant to section 319C–1; 
‘‘(B) the Strategic National Stockpile pur-
suant to section 319F–2; and 
‘‘(C) the Cities Readiness Initiative; and 
‘‘(4) assume other duties as determined appro-
priate by the Secretary.’’; and 
(3) by adding at the end the following: 
‘‘(d) PUBLIC HEALTH EMERGENCY MEDICAL COUN-
TERMEASURES ENTERPRISE STRATEGY AND IMPLEMENTA-
TION PLAN.— 
‘‘(1) IN
GENERAL.—Not later than 180 days 
after the date of enactment of this subsection, and 
every year thereafter, the Assistant Secretary for Pre-
paredness and Response shall develop and submit to 
the appropriate committees of Congress a coordinated 
strategy and accompanying implementation plan for 
medical countermeasures to address chemical, biologi-
cal, radiological, and nuclear threats. In developing 
such a plan, the Assistant Secretary for Preparedness 
and Response shall consult with the Director of the 
Biomedical Advanced Research and Development Au-
thority, the Director of the National Institutes of 
Health, the Director of the Centers for Disease Control 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00108
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
109 
and Prevention, and the Commissioner of Food and 
Drugs. Such strategy and plan shall be known as the 
‘Public Health Emergency Medical Countermeasures 
Enterprise Strategy and Implementation Plan’. 
‘‘(2) REQUIREMENTS.—The plan under para-
graph (1) shall— 
‘‘(A) describe the chemical, biological, radio-
logical, and nuclear agent or agents that may 
present a threat to the Nation and the cor-
responding efforts to develop qualified counter-
measures (as defined in section 319F–1), secu-
rity countermeasures (as defined in section 
319F–2), or qualified pandemic or epidemic 
products (as defined in section 319F–3) for each 
threat; 
‘‘(B) evaluate the progress of all activities 
with respect to such countermeasures or prod-
ucts, including research, advanced research, de-
velopment, procurement, stockpiling, deployment, 
distribution, and utilization; 
‘‘(C) identify and prioritize near-, mid-, 
and long-term needs with respect to such coun-
termeasures or products to address a chemical, 
biological, radiological, and nuclear threat or 
threats; 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00109
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
110 
‘‘(D) identify, with respect to each category 
of threat, a summary of all awards and con-
tracts, including advanced research and develop-
ment and procurement, that includes— 
‘‘(i) the time elapsed from the issuance 
of the initial solicitation or request for a 
proposal to the adjudication (such as the 
award, denial of award, or solicitation ter-
mination); and 
‘‘(ii) an identification of projected 
timelines, anticipated funding allocations, 
benchmarks, and milestones for each med-
ical countermeasure priority under sub-
paragraph (C), including projected needs 
with regard to replenishment of the Stra-
tegic National Stockpile; 
‘‘(E) be informed by the recommendations of 
the National Biodefense Science Board pursuant 
to section 319M; 
‘‘(F) evaluate progress made in meeting 
timelines, allocations, benchmarks, and mile-
stones identified under subparagraph (D)(ii); 
‘‘(G) report on the amount of funds avail-
able for procurement in the special reserve fund 
as defined in section 319F–2(h) and the impact 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00110
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
111 
this funding will have on meeting the require-
ments under section 319F–2; 
‘‘(H) incorporate input from Federal, State, 
local, and tribal stakeholders; 
‘‘(I) identify the progress made in meeting 
the medical countermeasure priorities for at-risk 
individuals (as defined in 2802(b)(4)(B)), as ap-
plicable under subparagraph (C), including with 
regard to the projected needs for related stock-
piling and replenishment of the Strategic Na-
tional Stockpile, including by addressing the 
needs of pediatric populations with respect to 
such countermeasures and products in the Stra-
tegic National Stockpile, including— 
‘‘(i) a list of such countermeasures and 
products necessary to address the needs of 
pediatric populations; 
‘‘(ii) a description of measures taken to 
coordinate with the Office of Pediatric 
Therapeutics of the Food and Drug Admin-
istration to maximize the labeling, dosages, 
and formulations of such countermeasures 
and products for pediatric populations; 
‘‘(iii) a description of existing gaps in 
the Strategic National Stockpile and the de-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00111
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
112 
velopment of such countermeasures and 
products to address the needs of pediatric 
populations; and 
‘‘(iv) an evaluation of the progress 
made in addressing priorities identified 
pursuant to subparagraph (C); 
‘‘(J) identify the use of authority and ac-
tivities undertaken pursuant to sections 319F– 
1(b)(1), 319F–1(b)(2), 319F–1(b)(3), 319F–1(c), 
319F–1(d), 
319F–1(e), 
319F–2(c)(7)(C)(iii), 
319F–2(c)(7)(C)(iv), and 319F–2(c)(7)(C)(v) of 
this Act, and subsections (a)(1), (b)(1), and (e) 
of section 564 of the Federal Food, Drug, and 
Cosmetic Act, by summarizing— 
‘‘(i) the particular actions that were 
taken under the authorities specified, in-
cluding, as applicable, the identification of 
the threat agent, emergency, or the bio-
medical countermeasure with respect to 
which the authority was used; 
‘‘(ii) the reasons underlying the deci-
sion to use such authorities, including, as 
applicable, the options that were considered 
and rejected with respect to the use of such 
authorities; 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00112
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
113 
‘‘(iii) the number of, nature of, and 
other information concerning the persons 
and entities that received a grant, coopera-
tive agreement, or contract pursuant to the 
use of such authorities, and the persons and 
entities that were considered and rejected 
for such a grant, cooperative agreement, or 
contract, except that the report need not dis-
close the identity of any such person or en-
tity; 
‘‘(iv) whether, with respect to each pro-
curement that is approved by the President 
under section 319F–2(c)(6), a contract was 
entered into within one year after such ap-
proval by the President; and 
‘‘(v) with respect to section 319F–1(d), 
for the one-year period for which the report 
is submitted, the number of persons who 
were paid amounts totaling $100,000 or 
greater and the number of persons who were 
paid amounts totaling at least $50,000 but 
less than $100,000; and 
‘‘(K) be made publicly available. 
‘‘(3) GAO REPORT.— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00113
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
114 
‘‘(A) IN GENERAL.—Not later than 1 year 
after the date of the submission to the Congress 
of the first Public Health Emergency Medical 
Countermeasures Enterprise Strategy and Imple-
mentation Plan, the Comptroller General of the 
United States shall conduct an independent eval-
uation, and submit to the appropriate commit-
tees of Congress a report, concerning such Strat-
egy and Implementation Plan. 
‘‘(B) CONTENT.—The report described in 
subparagraph (A) shall review and assess— 
‘‘(i) the near-term, mid-term, and 
long-term medical countermeasure needs 
and identified priorities of the Federal Gov-
ernment pursuant to paragraph (2)(C); 
‘‘(ii) the activities of the Department of 
Health and Human Services with respect to 
advanced research and development pursu-
ant to section 319L; and 
‘‘(iii) the progress made toward meet-
ing the timelines, allocations, benchmarks, 
and milestones identified in the Public 
Health 
Emergency 
Medical 
Counter-
measures Enterprise Strategy and Imple-
mentation Plan under this subsection. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00114
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
115 
‘‘(e) PROTECTION OF NATIONAL SECURITY.—In car-
rying out subsections (b)(7) and (d), the Secretary shall en-
sure that information and items that could compromise na-
tional security, contain confidential commercial informa-
tion, or contain proprietary information are not dis-
closed.’’. 
(b) INTERAGENCY COORDINATION PLAN.—In the first 
Public Health Emergency Countermeasures Enterprise 
Strategy and Implementation Plan submitted under sub-
section (d) of section 2811 of the Public Health Service Act 
(42 U.S.C. 300hh–10) (as added by subsection (a)(3)), the 
Secretary of Health and Human Services, in consultation 
with the Secretary of Defense, shall include a description 
of the manner in which the Department of Health and 
Human Services is coordinating with the Department of 
Defense regarding countermeasure activities to address 
chemical, biological, radiological, and nuclear threats. Such 
report shall include information with respect to— 
(1) the research, advanced research, development, 
procurement, stockpiling, and distribution of counter-
measures to meet identified needs; and 
(2) the coordination of efforts between the De-
partment of Health and Human Services and the De-
partment of Defense to address countermeasure needs 
for various segments of the population. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00115
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
116 
SEC. 103. NATIONAL ADVISORY COMMITTEE ON CHILDREN 
AND DISASTERS. 
Subtitle B of title XXVIII of the Public Health Service 
Act (42 U.S.C. 300hh et seq.) is amended by inserting after 
section 2811 the following: 
‘‘SEC. 2811A. NATIONAL ADVISORY COMMITTEE ON CHIL-
DREN AND DISASTERS. 
‘‘(a) ESTABLISHMENT.—The Secretary, in consulta-
tion with the Secretary of Homeland Security, shall estab-
lish an advisory committee to be known as the ‘National 
Advisory Committee on Children and Disasters’ (referred 
to in this section as the ‘Advisory Committee’). 
‘‘(b) DUTIES.—The Advisory Committee shall— 
‘‘(1) provide advice and consultation with re-
spect to the activities carried out pursuant to section 
2814, as applicable and appropriate; 
‘‘(2) evaluate and provide input with respect to 
the medical and public health needs of children as 
they relate to preparation for, response to, and recov-
ery from all-hazards emergencies; and 
‘‘(3) provide advice and consultation with re-
spect to State emergency preparedness and response 
activities and children, including related drills and 
exercises pursuant to the preparedness goals under 
section 2802(b). 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00116
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
117 
‘‘(c) ADDITIONAL DUTIES.—The Advisory Committee 
may provide advice and recommendations to the Secretary 
with respect to children and the medical and public health 
grants and cooperative agreements as applicable to pre-
paredness and response activities authorized under this title 
and title III. 
‘‘(d) MEMBERSHIP.— 
‘‘(1) IN GENERAL.—The Secretary, in consulta-
tion with such other Secretaries as may be appro-
priate, shall appoint not to exceed 15 members to the 
Advisory Committee. In appointing such members, 
the Secretary shall ensure that the total membership 
of the Advisory Committee is an odd number. 
‘‘(2) REQUIRED MEMBERS.—The Secretary, in 
consultation with such other Secretaries as may be 
appropriate, may appoint to the Advisory Committee 
under paragraph (1) such individuals as may be ap-
propriate to perform the duties described in sub-
sections (b) and (c), which may include— 
‘‘(A) the Assistant Secretary for Prepared-
ness and Response; 
‘‘(B) the Director of the Biomedical Ad-
vanced Research and Development Authority; 
‘‘(C) the Director of the Centers for Disease 
Control and Prevention; 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00117
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
118 
‘‘(D) the Commissioner of Food and Drugs; 
‘‘(E) the Director of the National Institutes 
of Health; 
‘‘(F) the Assistant Secretary of the Admin-
istration for Children and Families; 
‘‘(G) the Administrator of the Federal 
Emergency Management Agency; 
‘‘(H) at least two non-Federal health care 
professionals with expertise in pediatric medical 
disaster planning, preparedness, response, or re-
covery; 
‘‘(I) at least two representatives from State, 
local, territorial, or tribal agencies with expertise 
in pediatric disaster planning, preparedness, re-
sponse, or recovery; and 
‘‘(J) representatives from such Federal 
agencies (such as the Department of Education 
and the Department of Homeland Security) as 
determined necessary to fulfill the duties of the 
Advisory Committee, as established under sub-
sections (b) and (c). 
‘‘(e) MEETINGS.—The Advisory Committee shall meet 
not less than biannually. 
‘‘(f) SUNSET.—The Advisory Committee shall termi-
nate on September 30, 2018.’’. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00118
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
119 
SEC. 104. MODERNIZATION OF THE NATIONAL DISASTER 
MEDICAL SYSTEM. 
Section 2812 of the Public Health Service Act (42 
U.S.C. 300hh–11) is amended— 
(1) in subsection (a)(3)— 
(A) in subparagraph (A), in clause (i) by 
inserting ‘‘, including at-risk individuals as ap-
plicable’’ after ‘‘victims of a public health emer-
gency’’; 
(B) by redesignating subparagraph (C) as 
subparagraph (E); and 
(C) by inserting after subparagraph (B), 
the following: 
‘‘(C) CONSIDERATIONS FOR AT-RISK POPU-
LATIONS.—The Secretary shall take steps to en-
sure that an appropriate specialized and focused 
range of public health and medical capabilities 
are represented in the National Disaster Medical 
System, which take into account the needs of at- 
risk individuals, in the event of a public health 
emergency.’’. 
‘‘(D) 
ADMINISTRATION.—The 
Secretary 
may determine and pay claims for reimburse-
ment for services under subparagraph (A) di-
rectly or through contracts that provide for pay-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00119
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
120 
ment in advance or by way of reimbursement.’’; 
and 
(2) in subsection (g), by striking ‘‘such sums as 
may be necessary for each of the fiscal years 2007 
through 2011’’ and inserting ‘‘$52,700,000 for each of 
fiscal years 2014 through 2018’’. 
SEC. 105. CONTINUING THE ROLE OF THE DEPARTMENT OF 
VETERANS AFFAIRS. 
Section 8117(g) of title 38, United States Code, is 
amended by striking ‘‘such sums as may be necessary to 
carry out this section for each of fiscal years 2007 through 
2011’’ and inserting ‘‘$155,300,000 for each of fiscal years 
2014 through 2018 to carry out this section’’. 
TITLE 
II—OPTIMIZING 
STATE 
AND 
LOCAL 
ALL-HAZARDS 
PREPAREDNESS 
AND 
RE-
SPONSE 
SEC. 201. TEMPORARY REASSIGNMENT OF STATE AND 
LOCAL 
PERSONNEL 
DURING 
A 
PUBLIC 
HEALTH EMERGENCY. 
Section 319 of the Public Health Service Act (42 
U.S.C. 247d) is amended by adding at the end the fol-
lowing: 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00120
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
121 
‘‘(e) TEMPORARY
REASSIGNMENT
OF
STATE
AND 
LOCAL PERSONNEL DURING A PUBLIC HEALTH EMER-
GENCY.— 
‘‘(1) EMERGENCY REASSIGNMENT OF FEDERALLY 
FUNDED
PERSONNEL.—Notwithstanding any other 
provision of law, and subject to paragraph (2), upon 
request by the Governor of a State or a tribal organi-
zation or such Governor or tribal organization’s des-
ignee, the Secretary may authorize the requesting 
State or Indian tribe to temporarily reassign, for 
purposes of immediately addressing a public health 
emergency in the State or Indian tribe, State and 
local public health department or agency personnel 
funded in whole or in part through programs author-
ized under this Act, as appropriate. 
‘‘(2) ACTIVATION
OF
EMERGENCY
REASSIGN-
MENT.— 
‘‘(A) PUBLIC
HEALTH
EMERGENCY.—The 
Secretary may authorize a temporary reassign-
ment of personnel under paragraph (1) only dur-
ing the period of a public health emergency de-
termined pursuant to subsection (a). 
‘‘(B) CONTENTS OF REQUEST.—To seek au-
thority for a temporary reassignment of per-
sonnel under paragraph (1), the Governor of a 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00121
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
122 
State or a tribal organization shall submit to the 
Secretary a request for such reassignment flexi-
bility and shall include in the request each of the 
following: 
‘‘(i) An assurance that the public 
health emergency in the geographic area of 
the requesting State or Indian tribe cannot 
be adequately and appropriately addressed 
by the public health workforce otherwise 
available. 
‘‘(ii) An assurance that the public 
health emergency would be addressed more 
efficiently and effectively through the re-
quested temporary reassignment of State 
and local personnel described in paragraph 
(1). 
‘‘(iii) An assurance that the requested 
temporary reassignment of personnel is con-
sistent with any applicable All-Hazards 
Public Health Emergency Preparedness and 
Response Plan under section 319C–1. 
‘‘(iv) An identification of— 
‘‘(I) each Federal program from 
which personnel would be temporarily 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00122
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
123 
reassigned pursuant to the requested 
authority; and 
‘‘(II) the number of personnel who 
would be so reassigned from each such 
program. 
‘‘(v) Such other information and as-
surances upon which the Secretary and 
Governor of a State or tribal organization 
agree. 
‘‘(C) CONSIDERATION.—In reviewing a re-
quest for temporary reassignment under para-
graph (1), the Secretary shall consider the degree 
to which the program or programs funded in 
whole or in part by programs authorized under 
this Act would be adversely affected by the reas-
signment. 
‘‘(D) TERMINATION AND EXTENSION.— 
‘‘(i) TERMINATION.—A State or Indian 
tribe’s temporary reassignment of personnel 
under paragraph (1) shall terminate upon 
the earlier of the following: 
‘‘(I) The Secretary’s determina-
tion that the public health emergency 
no longer exists. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00123
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
124 
‘‘(II) Subject to clause (ii), the ex-
piration of the 30-day period following 
the date on which the Secretary ap-
proved the State or Indian tribe’s re-
quest for such reassignment flexibility. 
‘‘(ii) EXTENSION
OF
REASSIGNMENT 
FLEXIBILITY.—The Secretary may extend 
reassignment flexibility of personnel under 
paragraph (1) beyond the date otherwise 
applicable under clause (i)(II) if the public 
health emergency still exists as of such date, 
but only if— 
‘‘(I) the State or Indian tribe that 
submitted the initial request for a tem-
porary reassignment of personnel sub-
mits a request for an extension of such 
temporary reassignment; and 
‘‘(II) the request for an extension 
contains the same information and as-
surances necessary for the approval of 
an initial request for such temporary 
reassignment pursuant to subpara-
graph (B). 
‘‘(3) VOLUNTARY NATURE OF TEMPORARY REAS-
SIGNMENT OF STATE AND LOCAL PERSONNEL.— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00124
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
125 
‘‘(A) IN GENERAL.—Unless otherwise pro-
vided under the law or regulation of the State or 
Indian tribe that receives authorization for tem-
porary reassignment of personnel under para-
graph (1), personnel eligible for reassignment 
pursuant to such authorization— 
‘‘(i) shall have the opportunity to vol-
unteer for temporary reassignment; and 
‘‘(ii) shall not be required to agree to 
a temporary reassignment. 
‘‘(B) PROHIBITION ON CONDITIONING FED-
ERAL AWARDS.—The Secretary may not condi-
tion the award of a grant, contract, or coopera-
tive agreement under this Act on the requirement 
that a State or Indian tribe require that per-
sonnel eligible for reassignment pursuant to an 
authorization under paragraph (1) agree to such 
reassignment. 
‘‘(4) NOTICE TO CONGRESS.—The Secretary shall 
give notice to the Congress in conjunction with the 
approval under this subsection of— 
‘‘(A) any initial request for temporary reas-
signment of personnel; and 
‘‘(B) any request for an extension of such 
temporary reassignment. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00125
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
126 
‘‘(5) GUIDANCE.—The Secretary shall— 
‘‘(A) not later than 6 months after the en-
actment of this subsection, issue proposed guid-
ance on the temporary reassignment of personnel 
under this subsection; and 
‘‘(B) after providing notice and a 60-day 
period for public comment, finalize such guid-
ance. 
‘‘(6) REPORT TO CONGRESS.—Not later than 4 
years after the date of enactment of the Pandemic and 
All-Hazards Preparedness Reauthorization Act of 
2013, the Comptroller General of the United States 
shall conduct an independent evaluation, and submit 
to the appropriate committees of the Congress a re-
port, on temporary reassignment under this sub-
section, including— 
‘‘(A) a description of how, and under what 
circumstances, such temporary reassignment has 
been used by States and Indian tribes; 
‘‘(B) an analysis of how such temporary re-
assignment has assisted States and Indian tribes 
in responding to public health emergencies; 
‘‘(C) an evaluation of how such temporary 
reassignment has improved operational effi-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00126
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
127 
ciencies in responding to public health emer-
gencies; 
‘‘(D) an analysis of the extent to which, if 
any, Federal programs from which personnel 
have been temporarily reassigned have been ad-
versely affected by the reassignment; and 
‘‘(E) recommendations on how medical 
surge capacity could be improved in responding 
to public health emergencies and the impact of 
the reassignment flexibility under this section on 
such surge capacity. 
‘‘(7) DEFINITIONS.—In this subsection— 
‘‘(A) the terms ‘Indian tribe’ and ‘tribal or-
ganization’ have the meanings given such terms 
in section 4 of the Indian Self-Determination 
and Education Assistance Act; and 
‘‘(B) the term ‘State’ includes, in addition 
to the entities listed in the definition of such 
term in section 2, the Freely Associated States. 
‘‘(8) SUNSET.—This subsection shall terminate 
on September 30, 2018.’’. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00127
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
128 
SEC. 202. IMPROVING STATE AND LOCAL PUBLIC HEALTH 
SECURITY. 
(a) COOPERATIVE AGREEMENTS.—Section 319C–1 of 
the Public Health Service Act (42 U.S.C. 247d–3a) is 
amended— 
(1) in subsection (b)(1)(C), by striking ‘‘consor-
tium of entities described in subparagraph (A)’’ and 
inserting ‘‘consortium of States’’; 
(2) in subsection (b)(2)— 
(A) in subparagraph (A)— 
(i) by striking clauses (i) and (ii) and 
inserting the following: 
‘‘(i) a description of the activities such 
entity will carry out under the agreement to 
meet the goals identified under section 2802, 
including with respect to chemical, biologi-
cal, radiological, or nuclear threats, whether 
naturally occurring, unintentional, or delib-
erate; 
‘‘(ii) a description of the activities such 
entity will carry out with respect to pan-
demic influenza, as a component of the ac-
tivities carried out under clause (i), and 
consistent with the requirements of para-
graphs (2) and (5) of subsection (g);’’; 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00128
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
129 
(ii) in clause (iv), by striking ‘‘and’’ at 
the end; and 
(iii) by adding at the end the fol-
lowing: 
‘‘(vi) a description of how, as appro-
priate, the entity may partner with relevant 
public and private stakeholders in public 
health emergency preparedness and re-
sponse; 
‘‘(vii) a description of how the entity, 
as applicable and appropriate, will coordi-
nate with State emergency preparedness 
and response plans in public health emer-
gency preparedness, including State edu-
cational agencies (as defined in section 
9101(41) of the Elementary and Secondary 
Education Act of 1965) and State child care 
lead agencies (designated under section 
658D of the Child Care and Development 
Block Grant Act of 1990); 
‘‘(viii) in the case of entities that oper-
ate on the United States-Mexico border or 
the United States-Canada border, a descrip-
tion of the activities such entity will carry 
out under the agreement that are specific to 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00129
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
130 
the border area including disease detection, 
identification, investigation, and prepared-
ness and response activities related to 
emerging diseases and infectious disease 
outbreaks whether naturally occurring or 
due to bioterrorism, consistent with the re-
quirements of this section; and 
‘‘(ix) a description of any activities 
that such entity will use to analyze real- 
time clinical specimens for pathogens of 
public health or bioterrorism significance, 
including any utilization of poison control 
centers;’’; and 
(B) in subparagraph (C), by inserting ‘‘, 
including addressing the needs of at-risk individ-
uals,’’ after ‘‘capabilities of such entity’’; 
(3) in subsection (f)— 
(A) in paragraph (2), by adding ‘‘and’’ at 
the end; 
(B) in paragraph (3), by striking ‘‘; and’’ 
and inserting a period; and 
(C) by striking paragraph (4); 
(4) in subsection (g)— 
(A) in paragraph (1), by striking subpara-
graph (A) and inserting the following: 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00130
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
131 
‘‘(A) include outcome goals representing 
operational achievements of the National Pre-
paredness Goals developed under section 2802(b) 
with respect to all-hazards, including chemical, 
biological, radiological, or nuclear threats; and’’; 
and 
(B) in paragraph (2)(A), by adding at the 
end the following: ‘‘The Secretary shall periodi-
cally update, as necessary and appropriate, such 
pandemic influenza plan criteria and shall re-
quire the integration of such criteria into the 
benchmarks and standards described in para-
graph (1).’’; 
(5) by striking subsection (h); 
(6) by redesignating subsections (i), (j), and (k) 
as subsections (h), (i), and (j), respectively; 
(7) in subsection (h), as so redesignated— 
(A) in paragraph (1)— 
(i) in subparagraph (A)— 
(I) by striking ‘‘$824,000,000 for 
fiscal year 2007, of which $35,000,000 
shall be used to carry out subsection 
(h),’’ and inserting ‘‘$641,900,000 for 
fiscal year 2014’’; and 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00131
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
132 
(II) by striking ‘‘such sums as 
may be necessary for each of fiscal 
years 2008 through 2011’’ and insert-
ing ‘‘$641,900,000 for each of fiscal 
years 2015 through 2018’’; 
(ii) by striking subparagraph (B); 
(iii) by redesignating subparagraphs 
(C) and (D) as subparagraphs (B) and (C), 
respectively; and 
(iv) in subparagraph (C), as so redes-
ignated, by striking ‘‘subparagraph (C)’’ 
and inserting ‘‘subparagraph (B)’’; 
(B) in subparagraphs (C) and (D) of para-
graph (3), by striking ‘‘(1)(A)(i)(I)’’ each place 
it appears and inserting ‘‘(1)(A)’’; 
(C) in paragraph (4)(B), by striking ‘‘sub-
section (c)’’ and inserting ‘‘subsection (b)’’; and 
(D) by adding at the end the following: 
‘‘(7) AVAILABILITY OF COOPERATIVE AGREEMENT 
FUNDS.— 
‘‘(A) IN
GENERAL.—Amounts provided to 
an eligible entity under a cooperative agreement 
under subsection (a) for a fiscal year and re-
maining unobligated at the end of such year 
shall remain available to such entity for the next 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00132
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
133 
fiscal year for the purposes for which such funds 
were provided. 
‘‘(B) FUNDS
CONTINGENT
ON
ACHIEVING 
BENCHMARKS.—The continued availability of 
funds under subparagraph (A) with respect to an 
entity shall be contingent upon such entity 
achieving the benchmarks and submitting the 
pandemic influenza plan as described in sub-
section (g).’’; and 
(8) in subsection (i), as so redesignated— 
(A) in paragraph (1)(E), by striking ‘‘sub-
section (k)’’ and inserting ‘‘subsection (j)’’; 
(B) by striking paragraph (3). 
(b) VACCINE TRACKING AND DISTRIBUTION.—Section 
319A(e) of the Public Health Service Act (42 U.S.C. 247d– 
1(e)) is amended by striking ‘‘such sums for each of fiscal 
years 2007 through 2011’’ and inserting ‘‘$30,800,000 for 
each of fiscal years 2014 through 2018’’. 
(c) TECHNICAL AND CONFORMING AMENDMENTS.— 
(1) Section 319C–1(b)(1)(B) of the Public Health 
Service Act (42 U.S.C. 247d–3a(b)(1)(B)) is amended 
by striking ‘‘subsection (i)(4)’’ and inserting ‘‘sub-
section (h)(4)’’. 
(2) Section 319C–2 of the Public Health Service 
Act (42 U.S.C. 247d–3b) is amended— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00133
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
134 
(A) in subsection (i), by striking ‘‘(j), and 
(k)’’ and inserting ‘‘(i), and (j)’’; and 
(B) in subsection (j)(3), by striking ‘‘319C– 
1(i)’’ and inserting ‘‘319C–1(h)’’. 
SEC. 203. HOSPITAL PREPAREDNESS AND MEDICAL SURGE 
CAPACITY. 
(a) ALL-HAZARDS PUBLIC HEALTH AND MEDICAL 
RESPONSE
CURRICULA
AND
TRAINING.—Section 
319F(a)(5)(B) of the Public Health Service Act (42 U.S.C. 
247d–6(a)(5)(B)) is amended by striking ‘‘public health or 
medical’’ and inserting ‘‘public health, medical, or dental’’. 
(b) ENCOURAGING HEALTH PROFESSIONAL VOLUN-
TEERS.— 
(1) EMERGENCY
SYSTEM
FOR
ADVANCE
REG-
ISTRATION
OF
VOLUNTEER
HEALTH
PROFES-
SIONALS.—Section 319I(k) of the Public Health Serv-
ice Act (42 U.S.C. 247d–7b(k)) is amended by strik-
ing ‘‘$2,000,000 for fiscal year 2002, and such sums 
as may be necessary for each of the fiscal years 2003 
through 2011’’ and inserting ‘‘$5,000,000 for each of 
fiscal years 2014 through 2018’’. 
(2) VOLUNTEERS.—Section 2813 of the Public 
Health Service Act (42 U.S.C. 300hh–15) is amend-
ed— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00134
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
135 
(A) in subsection (d)(2), by adding at the 
end the following: ‘‘Such training exercises shall, 
as appropriate and applicable, incorporate the 
needs of at-risk individuals in the event of a 
public health emergency.’’; and 
(B) 
in 
subsection 
(i), 
by 
striking 
‘‘$22,000,000 for fiscal year 2007, and such sums 
as may be necessary for each of fiscal years 2008 
through 2011’’ and inserting ‘‘$11,200,000 for 
each of fiscal years 2014 through 2018’’. 
(c) PARTNERSHIPS FOR STATE AND REGIONAL PRE-
PAREDNESS
TO
IMPROVE
SURGE
CAPACITY.—Section 
319C–2 of the Public Health Service Act (42 U.S.C. 247d– 
3b) is amended— 
(1) in subsection (a), by inserting ‘‘, including, 
as appropriate, capacity and preparedness to address 
the needs of children and other at-risk individuals’’ 
before the period at the end; 
(2) in subsection (b)(1)(A)(ii), by striking ‘‘cen-
ters, primary’’ and inserting ‘‘centers, community 
health centers, primary’’; 
(3) by striking subsection (c) and inserting the 
following: 
‘‘(c) USE OF FUNDS.—An award under subsection (a) 
shall be expended for activities to achieve the preparedness 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00135
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
136 
goals described under paragraphs (1), (3), (4), (5), and (6) 
of section 2802(b) with respect to all-hazards, including 
chemical, biological, radiological, or nuclear threats.’’; 
(4) by striking subsection (g) and inserting the 
following: 
‘‘(g) COORDINATION.— 
‘‘(1) LOCAL RESPONSE CAPABILITIES.—An eligi-
ble entity shall, to the extent practicable, ensure that 
activities carried out under an award under sub-
section (a) are coordinated with activities of relevant 
local Metropolitan Medical Response Systems, local 
Medical Reserve Corps, the local Cities Readiness Ini-
tiative, and local emergency plans. 
‘‘(2) NATIONAL
COLLABORATION.—Partnerships 
consisting of one or more eligible entities under this 
section may, to the extent practicable, collaborate 
with other partnerships consisting of one or more eli-
gible entities under this section for purposes of na-
tional coordination and collaboration with respect to 
activities to achieve the preparedness goals described 
under paragraphs (1), (3), (4), (5), and (6) of section 
2802(b).’’; 
(5) in subsection (i)— 
(A) by striking ‘‘The requirements of’’ and 
inserting the following: 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00136
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
137 
‘‘(1) IN GENERAL.—The requirements of’’; and 
(B) by adding at the end the following: 
‘‘(2) MEETING GOALS OF NATIONAL HEALTH SE-
CURITY STRATEGY.—The Secretary shall implement 
objective, evidence-based metrics to ensure that enti-
ties receiving awards under this section are meeting, 
to the extent practicable, the applicable goals of the 
National Health Security Strategy under section 
2802.’’; and 
(6) in subsection (j)— 
(A) by amending paragraph (1) to read as 
follows: 
‘‘(1) IN GENERAL.—For purposes of carrying out 
this section, there is authorized to be appropriated 
$374,700,000 for each of fiscal years 2014 through 
2018.’’; and 
(B) by adding at the end the following: 
‘‘(4) AVAILABILITY OF COOPERATIVE AGREEMENT 
FUNDS.— 
‘‘(A) IN
GENERAL.—Amounts provided to 
an eligible entity under a cooperative agreement 
under subsection (a) for a fiscal year and re-
maining unobligated at the end of such year 
shall remain available to such entity for the next 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00137
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
138 
fiscal year for the purposes for which such funds 
were provided. 
‘‘(B) FUNDS
CONTINGENT
ON
ACHIEVING 
BENCHMARKS.—The continued availability of 
funds under subparagraph (A) with respect to an 
entity shall be contingent upon such entity 
achieving the benchmarks and submitting the 
pandemic influenza plan as required under sub-
section (i).’’. 
SEC. 204. ENHANCING SITUATIONAL AWARENESS AND BIO-
SURVEILLANCE. 
(a) IN GENERAL.—Section 319D of the Public Health 
Service Act (42 U.S.C. 247d–4) is amended— 
(1) in subsection (b)— 
(A) in paragraph (1)(B), by inserting ‘‘poi-
son control centers,’’ after ‘‘hospitals,’’; 
(B) in paragraph (2), by inserting before 
the period at the end the following: ‘‘, allowing 
for coordination to maximize all-hazards medical 
and public health preparedness and response and 
to minimize duplication of effort’’; and 
(C) in paragraph (3), by inserting before 
the period at the end the following: ‘‘and update 
such standards as necessary’’; 
(2) by striking subsection (c); 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00138
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
139 
(3) by redesignating subsections (d) through (g) 
as subsections (c) through (f), respectively; 
(4) in subsection (c), as so redesignated— 
(A) in the subsection heading, by striking 
‘‘PUBLIC HEALTH SITUATIONAL AWARENESS’’ 
and inserting ‘‘MODERNIZING PUBLIC HEALTH 
SITUATIONAL
AWARENESS
AND
BIOSURVEIL-
LANCE’’; 
(B) in paragraph (1)— 
(i) by striking ‘‘Pandemic and All- 
Hazards Preparedness Act’’ and inserting 
‘‘Pandemic and All-Hazards Preparedness 
Reauthorization Act of 2013’’; and 
(ii) by inserting ‘‘, novel emerging 
threats,’’ after ‘‘disease outbreaks’’; 
(C) by striking paragraph (2) and inserting 
the following: 
‘‘(2) STRATEGY AND IMPLEMENTATION PLAN.— 
Not later than 180 days after the date of enactment 
of the Pandemic and All-Hazards Preparedness Reau-
thorization Act of 2013, the Secretary shall submit to 
the appropriate committees of Congress a coordinated 
strategy and an accompanying implementation plan 
that identifies and demonstrates the measurable steps 
the Secretary will carry out to— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00139
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
140 
‘‘(A) develop, implement, and evaluate the 
network described in paragraph (1), utilizing the 
elements described in paragraph (3); 
‘‘(B) modernize and enhance biosurveillance 
activities; and 
‘‘(C) improve information sharing, coordi-
nation, and communication among disparate 
biosurveillance systems supported by the Depart-
ment of Health and Human Services.’’; 
(D) in paragraph (3)(D), by inserting 
‘‘community health centers, health centers’’ after 
‘‘poison control,’’; 
(E) in paragraph (5), by striking subpara-
graph (A) and inserting the following: 
‘‘(A) 
utilize 
applicable 
interoperability 
standards as determined by the Secretary, and 
in consultation with the Office of the National 
Coordinator for Health Information Technology, 
through a joint public and private sector proc-
ess;’’; and 
(F) by adding at the end the following: 
‘‘(6) CONSULTATION WITH THE NATIONAL BIO-
DEFENSE SCIENCE BOARD.—In carrying out this sec-
tion and consistent with section 319M, the National 
Biodefense Science Board shall provide expert advice 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00140
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
141 
and guidance, including recommendations, regarding 
the measurable steps the Secretary should take to 
modernize and enhance biosurveillance activities pur-
suant to the efforts of the Department of Health and 
Human Services to ensure comprehensive, real-time, 
all-hazards biosurveillance capabilities. In complying 
with the preceding sentence, the National Biodefense 
Science Board shall— 
‘‘(A) identify the steps necessary to achieve 
a national biosurveillance system for human 
health, with international connectivity, where 
appropriate, that is predicated on State, re-
gional, and community level capabilities and 
creates a networked system to allow for two-way 
information flow between and among Federal, 
State, and local government public health au-
thorities and clinical health care providers; 
‘‘(B) identify any duplicative surveillance 
programs under the authority of the Secretary, 
or changes that are necessary to existing pro-
grams, in order to enhance and modernize such 
activities, minimize duplication, strengthen and 
streamline such activities under the authority of 
the Secretary, and achieve real-time and appro-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00141
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
142 
priate data that relate to disease activity, both 
human and zoonotic; and 
‘‘(C) coordinate with applicable existing ad-
visory committees of the Director of the Centers 
for Disease Control and Prevention, including 
such advisory committees consisting of represent-
atives from State, local, and tribal public health 
authorities and appropriate public and private 
sector health care entities and academic institu-
tions, in order to provide guidance on public 
health surveillance activities.’’; 
(5) in subsection (d), as so redesignated— 
(A) in paragraph (1), by striking ‘‘sub-
section (d)’’ and inserting ‘‘subsection (c)’’; 
(B) in paragraph (4)(B), by striking ‘‘sub-
section (d)’’ and inserting ‘‘subsection (c)’’; and 
(C) in paragraph (5)— 
(i) by striking ‘‘4 years after the date 
of enactment of the Pandemic and All-Haz-
ards Preparedness Act’’ and inserting ‘‘3 
years after the date of enactment of the 
Pandemic and All-Hazards Preparedness 
Reauthorization Act of 2013’’; and 
(ii) by striking ‘‘subsection (d)’’ and 
inserting ‘‘subsection (c)’’; 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00142
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
143 
(6) in subsection (f), as so redesignated, by strik-
ing ‘‘such sums as may be necessary in each of fiscal 
years 
2007 
through 
2011’’ 
and 
inserting 
‘‘$138,300,000 for each of fiscal years 2014 through 
2018’’; and 
(7) by adding at the end the following: 
‘‘(g) DEFINITION.—For purposes of this section the 
term ‘biosurveillance’ means the process of gathering near 
real-time biological data that relates to human and zoonotic 
disease activity and threats to human or animal health, in 
order to achieve early warning and identification of such 
health threats, early detection and prompt ongoing tracking 
of health events, and overall situational awareness of disease 
activity.’’. 
(b) TECHNICAL AND CONFORMING AMENDMENT.—Sec-
tion 319C–1(b)(2)(D) of the Public Health Service Act (42 
U.S.C. 247d–3a(b)(2)(D)) is amended by striking ‘‘section 
319D(d)(3)’’ and inserting ‘‘section 319D(c)(3)’’. 
SEC. 205. ELIMINATING DUPLICATIVE PROJECT BIOSHIELD 
REPORTS. 
Section 5 of the Project Bioshield Act of 2004 (42 
U.S.C. 247d–6c) is repealed. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00143
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
144 
TITLE III—ENHANCING MEDICAL 
COUNTERMEASURE REVIEW 
SEC. 301. SPECIAL PROTOCOL ASSESSMENT. 
Section 505(b)(5)(B) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 355(b)(5)(B)) is amended by strik-
ing ‘‘size of clinical trials intended’’ and all that follows 
through ‘‘. The sponsor or applicant’’ and inserting the fol-
lowing: ‘‘size— 
‘‘(i)(I) of clinical trials intended to form the pri-
mary basis of an effectiveness claim; or 
‘‘(II) in the case where human efficacy studies 
are not ethical or feasible, of animal and any associ-
ated clinical trials which, in combination, are in-
tended to form the primary basis of an effectiveness 
claim; or 
‘‘(ii) with respect to an application for approval 
of a biological product under section 351(k) of the 
Public Health Service Act, of any necessary clinical 
study or studies. 
The sponsor or applicant’’. 
SEC. 302. AUTHORIZATION FOR MEDICAL PRODUCTS FOR 
USE IN EMERGENCIES. 
(a) IN GENERAL.—Section 564 of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 360bbb–3) is amend-
ed— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00144
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
145 
(1) in subsection (a)— 
(A) in paragraph (1), by striking ‘‘sections 
505, 510(k), and 515 of this Act’’ and inserting 
‘‘any provision of this Act’’; 
(B) in paragraph (2)(A), by striking 
‘‘under a provision of law referred to in such 
paragraph’’ and inserting ‘‘under section 505, 
510(k), or 515 of this Act or section 351 of the 
Public Health Service Act’’; and 
(C) in paragraph (3), by striking ‘‘a provi-
sion of law referred to in such paragraph’’ and 
inserting ‘‘a section of this Act or the Public 
Health Service Act referred to in paragraph 
(2)(A)’’; 
(2) in subsection (b)— 
(A) in the subsection heading, by striking 
‘‘EMERGENCY’’ and inserting ‘‘EMERGENCY OR 
THREAT JUSTIFYING EMERGENCY AUTHORIZED 
USE’’; 
(B) in paragraph (1)— 
(i) in the matter preceding subpara-
graph (A), by striking ‘‘may declare an 
emergency’’ and inserting ‘‘may make a 
declaration that the circumstances exist’’; 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00145
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
146 
(ii) in subparagraph (A), by striking 
‘‘specified’’; 
(iii) in subparagraph (B)— 
(I) by striking ‘‘specified’’; and 
(II) by striking ‘‘; or’’ and insert-
ing a semicolon; 
(iv) by amending subparagraph (C) to 
read as follows: 
‘‘(C) a determination by the Secretary that 
there is a public health emergency, or a signifi-
cant potential for a public health emergency, 
that affects, or has a significant potential to af-
fect, national security or the health and security 
of United States citizens living abroad, and that 
involves a biological, chemical, radiological, or 
nuclear agent or agents, or a disease or condition 
that may be attributable to such agent or agents; 
or’’; and 
(v) by adding at the end the following: 
‘‘(D) the identification of a material threat 
pursuant to section 319F–2 of the Public Health 
Service Act sufficient to affect national security 
or the health and security of United States citi-
zens living abroad.’’; 
(C) in paragraph (2)— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00146
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
147 
(i) in subparagraph (A), by amending 
clause (ii) to read as follows: 
‘‘(ii) a change in the approval status of 
the product such that the circumstances de-
scribed in subsection (a)(2) have ceased to 
exist.’’; 
(ii) by striking subparagraph (B); and 
(iii) by redesignating subparagraph 
(C) as subparagraph (B); 
(D) in paragraph (4), by striking ‘‘advance 
notice of termination, and renewal under this 
subsection.’’ and inserting ‘‘, and advance notice 
of termination under this subsection.’’; and 
(E) by adding at the end the following: 
‘‘(5) EXPLANATION BY SECRETARY.—If an au-
thorization under this section with respect to an un-
approved product or an unapproved use of an ap-
proved product has been in effect for more than 1 
year, the Secretary shall provide in writing to the 
sponsor of such product an explanation of the sci-
entific, regulatory, or other obstacles to approval, li-
censure, or clearance of such product or use, including 
specific actions to be taken by the Secretary and the 
sponsor to overcome such obstacles.’’; 
(3) in subsection (c)— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00147
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
148 
(A) in the matter preceding paragraph 
(1)— 
(i) by inserting ‘‘the Assistant Sec-
retary for Preparedness and Response,’’ 
after ‘‘consultation with’’; 
(ii) by striking ‘‘Health and’’ and in-
serting ‘‘Health, and’’; and 
(iii) by striking ‘‘circumstances of the 
emergency involved’’ and inserting ‘‘appli-
cable circumstances described in subsection 
(b)(1)’’; 
(B) in paragraph (1), by striking ‘‘speci-
fied’’ and inserting ‘‘referred to’’; and 
(C) in paragraph (2)(B), by inserting ‘‘, 
taking into consideration the material threat 
posed by the agent or agents identified in a dec-
laration under subsection (b)(1)(D), if applica-
ble’’ after ‘‘risks of the product’’; 
(4) in subsection (d)(3), by inserting ‘‘, to the ex-
tent practicable given the circumstances of the emer-
gency,’’ after ‘‘including’’; 
(5) in subsection (e)— 
(A) in paragraph (1)(A), by striking ‘‘cir-
cumstances of the emergency’’ and inserting ‘‘ap-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00148
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
149 
plicable circumstances described in subsection 
(b)(1)’’; 
(B) in paragraph (1)(B), by amending 
clause (iii) to read as follows: 
‘‘(iii) Appropriate conditions with re-
spect to collection and analysis of informa-
tion concerning the safety and effectiveness 
of the product with respect to the use of such 
product during the period when the author-
ization is in effect and a reasonable time 
following such period.’’; 
(C) in paragraph (2)— 
(i) in subparagraph (A)— 
(I) by striking ‘‘manufacturer of 
the product’’ and inserting ‘‘person’’; 
(II) by striking ‘‘circumstances of 
the emergency’’ and inserting ‘‘appli-
cable circumstances described in sub-
section (b)(1)’’; and 
(III) by inserting at the end be-
fore the period ‘‘or in paragraph 
(1)(B)’’; 
(ii) in subparagraph (B)(i), by insert-
ing before the period at the end ‘‘, except as 
provided in section 564A with respect to au-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00149
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
150 
thorized changes to the product expiration 
date’’; and 
(iii) by amending subparagraph (C) to 
read as follows: 
‘‘(C) In establishing conditions under this 
paragraph with respect to the distribution and 
administration of the product for the unap-
proved use, the Secretary shall not impose condi-
tions that would restrict distribution or adminis-
tration of the product when distributed or ad-
ministered for the approved use.’’; and 
(D) by amending paragraph (3) to read as 
follows: 
‘‘(3) GOOD
MANUFACTURING
PRACTICE; PRE-
SCRIPTION.—With respect to the emergency use of a 
product for which an authorization under this section 
is issued (whether an unapproved product or an un-
approved use of an approved product), the Secretary 
may waive or limit, to the extent appropriate given 
the applicable circumstances described in subsection 
(b)(1)— 
‘‘(A) requirements regarding current good 
manufacturing practice otherwise applicable to 
the manufacture, processing, packing, or holding 
of products subject to regulation under this Act, 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00150
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
151 
including such requirements established under 
section 501 or 520(f)(1), and including relevant 
conditions prescribed with respect to the product 
by an order under section 520(f)(2); 
‘‘(B) requirements established under section 
503(b); and 
‘‘(C) requirements established under section 
520(e).’’; 
(6) in subsection (g)— 
(A) in the subsection heading, by inserting 
‘‘REVIEW AND’’ before ‘‘REVOCATION’’; 
(B) in paragraph (1), by inserting after the 
period at the end the following: ‘‘As part of such 
review, the Secretary shall regularly review the 
progress made with respect to the approval, li-
censure, or clearance of— 
‘‘(A) an unapproved product for which an 
authorization was issued under this section; or 
‘‘(B) an unapproved use of an approved 
product for which an authorization was issued 
under this section.’’; and 
(C) by amending paragraph (2) to read as 
follows: 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00151
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
152 
‘‘(2) REVISION AND REVOCATION.—The Secretary 
may revise or revoke an authorization under this sec-
tion if— 
‘‘(A) the circumstances described under sub-
section (b)(1) no longer exist; 
‘‘(B) the criteria under subsection (c) for 
issuance of such authorization are no longer met; 
or 
‘‘(C) other circumstances make such revision 
or revocation appropriate to protect the public 
health or safety.’’; 
(7) in subsection (h)(1), by adding after the pe-
riod at the end the following: ‘‘The Secretary shall 
make any revisions to an authorization under this 
section available on the Internet Web site of the Food 
and Drug Administration.’’; 
(8) by adding at the end of subsection (j) the fol-
lowing: 
‘‘(4) Nothing in this section shall be construed as 
authorizing a delay in the review or other consider-
ation by the Secretary of any application or submis-
sion pending before the Food and Drug Administra-
tion for a product for which an authorization under 
this section is issued.’’; and 
(9) by adding at the end the following: 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00152
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
153 
‘‘(m) CATEGORIZATION OF LABORATORY TESTS ASSO-
CIATED WITH DEVICES SUBJECT TO AUTHORIZATION.— 
‘‘(1) IN GENERAL.—In issuing an authorization 
under this section with respect to a device, the Sec-
retary may, subject to the provisions of this section, 
determine that a laboratory examination or procedure 
associated with such device shall be deemed, for pur-
poses of section 353 of the Public Health Service Act, 
to be in a particular category of examinations and 
procedures (including the category described by sub-
section (d)(3) of such section) if, based on the totality 
of scientific evidence available to the Secretary— 
‘‘(A) such categorization would be beneficial 
to protecting the public health; and 
‘‘(B) the known and potential benefits of 
such categorization under the circumstances of 
the authorization outweigh the known and poten-
tial risks of the categorization. 
‘‘(2) CONDITIONS OF DETERMINATION.—The Sec-
retary may establish appropriate conditions on the 
performance of the examination or procedure pursu-
ant to such determination. 
‘‘(3) 
EFFECTIVE
PERIOD.—A 
determination 
under this subsection shall be effective for purposes of 
section 353 of the Public Health Service Act notwith-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00153
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
154 
standing any other provision of that section during 
the effective period of the relevant declaration under 
subsection (b).’’. 
(b) EMERGENCY USE OF MEDICAL PRODUCTS.—Sub-
chapter E of chapter V of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 360bbb et seq.) is amended by insert-
ing after section 564 the following: 
‘‘SEC. 564A. EMERGENCY USE OF MEDICAL PRODUCTS. 
‘‘(a) DEFINITIONS.—In this section: 
‘‘(1) ELIGIBLE
PRODUCT.—The term ‘eligible 
product’ means a product that— 
‘‘(A) is approved or cleared under this 
chapter or licensed under section 351 of the Pub-
lic Health Service Act; 
‘‘(B)(i) is intended for use to prevent, diag-
nose, or treat a disease or condition involving a 
biological, chemical, radiological, or nuclear 
agent or agents; or 
‘‘(ii) is intended for use to prevent, diag-
nose, or treat a serious or life-threatening disease 
or condition caused by a product described in 
clause (i); and 
‘‘(C) is intended for use during the cir-
cumstances under which— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00154
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
155 
‘‘(i) a determination described in sub-
paragraph (A), (B), or (C) of section 
564(b)(1) has been made by the Secretary of 
Homeland Security, the Secretary of De-
fense, or the Secretary, respectively; or 
‘‘(ii) the identification of a material 
threat described in subparagraph (D) of sec-
tion 564(b)(1) has been made pursuant to 
section 319F–2 of the Public Health Service 
Act. 
‘‘(2) PRODUCT.—The term ‘product’ means a 
drug, device, or biological product. 
‘‘(b) EXPIRATION DATING.— 
‘‘(1) IN GENERAL.—The Secretary may extend 
the expiration date and authorize the introduction or 
delivery for introduction into interstate commerce of 
an eligible product after the expiration date provided 
by the manufacturer if— 
‘‘(A) the expiration date extension is in-
tended to support the United States ability to 
protect— 
‘‘(i) the public health; or 
‘‘(ii) military preparedness and effec-
tiveness; and 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00155
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
156 
‘‘(B) the expiration date extension is sup-
ported by an appropriate scientific evaluation 
that is conducted or accepted by the Secretary. 
‘‘(2) REQUIREMENTS AND CONDITIONS.—Any ex-
tension of an expiration date under paragraph (1) 
shall, as part of the extension, identify— 
‘‘(A) each specific lot, batch, or other unit 
of the product for which extended expiration is 
authorized; 
‘‘(B) the duration of the extension; and 
‘‘(C) any other requirements or conditions 
as the Secretary may deem appropriate for the 
protection of the public health, which may in-
clude requirements for, or conditions on, product 
sampling, storage, packaging or repackaging, 
transport, labeling, notice to product recipients, 
recordkeeping, periodic testing or retesting, or 
product disposition. 
‘‘(3) EFFECT.—Notwithstanding any other pro-
vision of this Act or the Public Health Service Act, 
an eligible product shall not be considered an unap-
proved product (as defined in section 564(a)(2)(A)) 
and shall not be deemed adulterated or misbranded 
under this Act because, with respect to such product, 
the Secretary has, under paragraph (1), extended the 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00156
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
157 
expiration date and authorized the introduction or 
delivery for introduction into interstate commerce of 
such product after the expiration date provided by the 
manufacturer. 
‘‘(4) EXPIRATION DATE.—For purposes of this 
subsection, the term ‘expiration date’ means the date 
established through appropriate stability testing re-
quired by the regulations issued by the Secretary to 
ensure that the product meets applicable standards of 
identity, strength, quality, and purity at the time of 
use. 
‘‘(c) CURRENT GOOD MANUFACTURING PRACTICE.— 
‘‘(1) IN GENERAL.—The Secretary may, when 
the circumstances of a domestic, military, or public 
health emergency or material threat described in sub-
section (a)(1)(C) so warrant, authorize, with respect 
to an eligible product, deviations from current good 
manufacturing practice requirements otherwise appli-
cable to the manufacture, processing, packing, or 
holding of products subject to regulation under this 
Act, including requirements under section 501 or 
520(f)(1) or applicable conditions prescribed with re-
spect to the eligible product by an order under section 
520(f)(2). 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00157
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
158 
‘‘(2) EFFECT.—Notwithstanding any other pro-
vision of this Act or the Public Health Service Act, 
an eligible product shall not be considered an unap-
proved product (as defined in section 564(a)(2)(A)) 
and shall not be deemed adulterated or misbranded 
under this Act because, with respect to such product, 
the Secretary has authorized deviations from current 
good manufacturing practices under paragraph (1). 
‘‘(d) EMERGENCY DISPENSING.—The requirements of 
sections 503(b) and 520(e) shall not apply to an eligible 
product, and the product shall not be considered an unap-
proved product (as defined in section 564(a)(2)(A)) and 
shall not be deemed adulterated or misbranded under this 
Act because it is dispensed without an individual prescrip-
tion, if— 
‘‘(1) the product is dispensed during the cir-
cumstances described in subsection (a)(1)(C); and 
‘‘(2) such dispensing without an individual pre-
scription occurs— 
‘‘(A) as permitted under the law of the 
State in which the product is dispensed; or 
‘‘(B) in accordance with an order issued by 
the Secretary, for the purposes and duration of 
the 
circumstances 
described 
in 
subsection 
(a)(1)(C). 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00158
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
159 
‘‘(e) EMERGENCY USE INSTRUCTIONS.— 
‘‘(1) 
IN
GENERAL.—The 
Secretary, 
acting 
through an appropriate official within the Depart-
ment of Health and Human Services, may create and 
issue emergency use instructions to inform health care 
providers or individuals to whom an eligible product 
is to be administered concerning such product’s ap-
proved, licensed, or cleared conditions of use. 
‘‘(2) EFFECT.—Notwithstanding any other pro-
visions of this Act or the Public Health Service Act, 
a product shall not be considered an unapproved 
product and shall not be deemed adulterated or mis-
branded under this Act because of the issuance of 
emergency use instructions under paragraph (1) with 
respect to such product or the introduction or delivery 
for introduction of such product into interstate com-
merce accompanied by such instructions— 
‘‘(A) during an emergency response to an 
actual emergency that is the basis for a deter-
mination described in subsection (a)(1)(C)(i); or 
‘‘(B) by a government entity (including a 
Federal, State, local, or tribal government enti-
ty), or a person acting on behalf of such a gov-
ernment entity, in preparation for an emergency 
response.’’. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00159
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
160 
(c) RISK EVALUATION
AND MITIGATION STRATE-
GIES.—Section 505–1 of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 355–1), is amended— 
(1) in subsection (f), by striking paragraph (7); 
and 
(2) by adding at the end the following: 
‘‘(k) WAIVER IN PUBLIC HEALTH EMERGENCIES.— 
The Secretary may waive any requirement of this section 
with respect to a qualified countermeasure (as defined in 
section 319F–1(a)(2) of the Public Health Service Act) to 
which a requirement under this section has been applied, 
if the Secretary determines that such waiver is required to 
mitigate the effects of, or reduce the severity of, the cir-
cumstances under which— 
‘‘(1) a determination described in subparagraph 
(A), (B), or (C) of section 564(b)(1) has been made 
by the Secretary of Homeland Security, the Secretary 
of Defense, or the Secretary, respectively; or 
‘‘(2) the identification of a material threat de-
scribed in subparagraph (D) of section 564(b)(1) has 
been made pursuant to section 319F–2 of the Public 
Health Service Act.’’. 
(d) PRODUCTS HELD FOR EMERGENCY USE.—The 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00160
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
161 
seq.) is amended by inserting after section 564A, as added 
by subsection (b), the following: 
‘‘SEC. 564B. PRODUCTS HELD FOR EMERGENCY USE. 
‘‘It is not a violation of any section of this Act or of 
the Public Health Service Act for a government entity (in-
cluding a Federal, State, local, or tribal government entity), 
or a person acting on behalf of such a government entity, 
to introduce into interstate commerce a product (as defined 
in section 564(a)(4)) intended for emergency use, if that 
product— 
‘‘(1) is intended to be held and not used; and 
‘‘(2) is held and not used, unless and until that 
product— 
‘‘(A) is approved, cleared, or licensed under 
section 505, 510(k), or 515 of this Act or section 
351 of the Public Health Service Act; 
‘‘(B) is authorized for investigational use 
under section 505 or 520 of this Act or section 
351 of the Public Health Service Act; or 
‘‘(C) is authorized for use under section 
564.’’. 
SEC. 303. DEFINITIONS. 
Section 565 of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 360bbb–4) is amended by striking ‘‘The Sec-
retary, in consultation’’ and inserting the following: 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00161
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
162 
‘‘(a) DEFINITIONS.—In this section— 
‘‘(1) the term ‘countermeasure’ means a qualified 
countermeasure, a security countermeasure, and a 
qualified pandemic or epidemic product; 
‘‘(2) the term ‘qualified countermeasure’ has the 
meaning given such term in section 319F–1 of the 
Public Health Service Act; 
‘‘(3) the term ‘security countermeasure’ has the 
meaning given such term in section 319F–2 of such 
Act; and 
‘‘(4) the term ‘qualified pandemic or epidemic 
product’ means a product that meets the definition 
given such term in section 319F–3 of the Public 
Health Service Act and— 
‘‘(A) that has been identified by the Depart-
ment of Health and Human Services or the De-
partment of Defense as receiving funding directly 
related to addressing chemical, biological, radio-
logical, or nuclear threats, including pandemic 
influenza; or 
‘‘(B) is included under this paragraph pur-
suant to a determination by the Secretary. 
‘‘(b) GENERAL DUTIES.—The Secretary, in consulta-
tion’’. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00162
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
163 
SEC. 304. ENHANCING MEDICAL COUNTERMEASURE ACTIVI-
TIES. 
Section 565 of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 360bbb–4), as amended by section 303, is 
further amended— 
(1) in the section heading, by striking ‘‘TECH-
NICAL
ASSISTANCE’’ and inserting ‘‘COUNTER-
MEASURE DEVELOPMENT, REVIEW, AND TECH-
NICAL ASSISTANCE’’; 
(2) in subsection (b), by striking the subsection 
enumerator and all that follows through ‘‘shall estab-
lish’’ and inserting the following: 
‘‘(b) GENERAL DUTIES.—In order to accelerate the de-
velopment, stockpiling, approval, licensure, and clearance 
of qualified countermeasures, security countermeasures, and 
qualified pandemic or epidemic products, the Secretary, in 
consultation with the Assistant Secretary for Preparedness 
and Response, shall— 
‘‘(1) ensure the appropriate involvement of Food 
and Drug Administration personnel in interagency 
activities related to countermeasure advanced research 
and development, consistent with sections 319F, 
319F–1, 319F–2, 319F–3, 319L, and 2811 of the 
Public Health Service Act; 
‘‘(2) ensure the appropriate involvement and 
consultation of Food and Drug Administration per-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00163
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
164 
sonnel in any flexible manufacturing activities car-
ried out under section 319L of the Public Health 
Service Act, including with respect to meeting regu-
latory requirements set forth in this Act; 
‘‘(3) promote countermeasure expertise within 
the Food and Drug Administration by— 
‘‘(A) ensuring that Food and Drug Admin-
istration personnel involved in reviewing coun-
termeasures for approval, licensure, or clearance 
are informed by the Assistant Secretary for Pre-
paredness and Response on the material threat 
assessment conducted under section 319F–2 of 
the Public Health Service Act for the agent or 
agents for which the countermeasure under re-
view is intended; 
‘‘(B) training Food and Drug Administra-
tion personnel regarding review of counter-
measures for approval, licensure, or clearance; 
‘‘(C) holding public meetings at least twice 
annually to encourage the exchange of scientific 
ideas; and 
‘‘(D) establishing protocols to ensure that 
countermeasure reviewers have sufficient train-
ing or experience with countermeasures; 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00164
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
165 
‘‘(4) maintain teams, composed of Food and 
Drug Administration personnel with expertise on 
countermeasures, including specific countermeasures, 
populations with special clinical needs (including 
children and pregnant women that may use counter-
measures, as applicable and appropriate), classes or 
groups of countermeasures, or other countermeasure- 
related technologies and capabilities, that shall— 
‘‘(A) consult with countermeasure experts, 
including countermeasure sponsors and appli-
cants, to identify and help resolve scientific 
issues related to the approval, licensure, or clear-
ance of countermeasures, through workshops or 
public meetings; and 
‘‘(B) improve and advance the science relat-
ing to the development of new tools, standards, 
and approaches to assessing and evaluating 
countermeasures— 
‘‘(i) in order to inform the process for 
countermeasure approval, clearance, and li-
censure; and 
‘‘(ii) with respect to the development of 
countermeasures for populations with spe-
cial clinical needs, including children and 
pregnant women, in order to meet the needs 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00165
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
166 
of such populations, as necessary and ap-
propriate; and 
‘‘(5) establish’’; and 
(3) by adding at the end the following: 
‘‘(c) FINAL GUIDANCE ON DEVELOPMENT OF ANIMAL 
MODELS.— 
‘‘(1) IN GENERAL.—Not later than 1 year after 
the date of the enactment of the Pandemic and All- 
Hazards Preparedness Reauthorization Act of 2013, 
the Secretary shall provide final guidance to industry 
regarding the development of animal models to sup-
port approval, clearance, or licensure of counter-
measures referred to in subsection (a) when human ef-
ficacy studies are not ethical or feasible. 
‘‘(2) AUTHORITY
TO
EXTEND
DEADLINE.—The 
Secretary may extend the deadline for providing final 
guidance under paragraph (1) by not more than 6 
months upon submission by the Secretary of a report 
on the status of such guidance to the Committee on 
Energy and Commerce of the House of Representa-
tives and the Committee on Health, Education, 
Labor, and Pensions of the Senate. 
‘‘(d) DEVELOPMENT AND ANIMAL MODELING PROCE-
DURES.— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00166
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
167 
‘‘(1) AVAILABILITY
OF
ANIMAL
MODEL
MEET-
INGS.—To facilitate the timely development of animal 
models and support the development, stockpiling, li-
censure, approval, and clearance of countermeasures, 
the Secretary shall, not later than 180 days after the 
enactment of this subsection, establish a procedure by 
which a sponsor or applicant that is developing a 
countermeasure for which human efficacy studies are 
not ethical or practicable, and that has an approved 
investigational new drug application or investiga-
tional device exemption, may request and receive— 
‘‘(A) a meeting to discuss proposed animal 
model development activities; and 
‘‘(B) a meeting prior to initiating pivotal 
animal studies. 
‘‘(2) PEDIATRIC MODELS.—To facilitate the de-
velopment and selection of animal models that could 
translate to pediatric studies, any meeting conducted 
under paragraph (1) shall include discussion of ani-
mal models for pediatric populations, as appropriate. 
‘‘(e) 
REVIEW
AND
APPROVAL
OF
COUNTER-
MEASURES.— 
‘‘(1) MATERIAL THREAT.—When evaluating an 
application or submission for approval, licensure, or 
clearance of a countermeasure, the Secretary shall 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00167
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
168 
take into account the material threat posed by the 
chemical, biological, radiological, or nuclear agent or 
agents identified under section 319F–2 of the Public 
Health Service Act for which the countermeasure 
under review is intended. 
‘‘(2) REVIEW
EXPERTISE.—When practicable 
and appropriate, teams of Food and Drug Adminis-
tration personnel reviewing applications or submis-
sions described under paragraph (1) shall include a 
reviewer with sufficient training or experience with 
countermeasures pursuant to the protocols established 
under subsection (b)(3)(D).’’. 
SEC. 305. REGULATORY MANAGEMENT PLANS. 
Section 565 of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 360bbb–4), as amended by section 304, is 
further amended by adding at the end the following: 
‘‘(f) REGULATORY MANAGEMENT PLAN.— 
‘‘(1) DEFINITION.—In this subsection, the term 
‘eligible countermeasure’ means— 
‘‘(A) a security countermeasure with respect 
to which the Secretary has entered into a pro-
curement contract under section 319F–2(c) of the 
Public Health Service Act; or 
‘‘(B) a countermeasure with respect to 
which the Biomedical Advanced Research and 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00168
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
169 
Development Authority has provided funding 
under section 319L of the Public Health Service 
Act for advanced research and development. 
‘‘(2) REGULATORY
MANAGEMENT
PLAN
PROC-
ESS.—The Secretary, in consultation with the Assist-
ant Secretary for Preparedness and Response and the 
Director of the Biomedical Advanced Research and 
Development Authority, shall establish a formal proc-
ess for obtaining scientific feedback and interactions 
regarding the development and regulatory review of 
eligible countermeasures by facilitating the develop-
ment of written regulatory management plans in ac-
cordance with this subsection. 
‘‘(3) SUBMISSION OF REQUEST AND PROPOSED 
PLAN BY SPONSOR OR APPLICANT.— 
‘‘(A) IN GENERAL.—A sponsor or applicant 
of an eligible countermeasure may initiate the 
process described under paragraph (2) upon sub-
mission of a written request to the Secretary. 
Such request shall include a proposed regulatory 
management plan. 
‘‘(B) TIMING OF SUBMISSION.—A sponsor 
or applicant may submit a written request 
under subparagraph (A) after the eligible coun-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00169
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
170 
termeasure has an investigational new drug or 
investigational device exemption in effect. 
‘‘(C) RESPONSE BY SECRETARY.—The Sec-
retary shall direct the Food and Drug Adminis-
tration, upon submission of a written request by 
a sponsor or applicant under subparagraph (A), 
to work with the sponsor or applicant to agree 
on a regulatory management plan within a rea-
sonable time not to exceed 90 days. If the Sec-
retary determines that no plan can be agreed 
upon, the Secretary shall provide to the sponsor 
or applicant, in writing, the scientific or regu-
latory rationale why such agreement cannot be 
reached. 
‘‘(4) PLAN.—The content of a regulatory man-
agement plan agreed to by the Secretary and a spon-
sor or applicant shall include— 
‘‘(A) an agreement between the Secretary 
and the sponsor or applicant regarding develop-
mental milestones that will trigger responses by 
the Secretary as described in subparagraph (B); 
‘‘(B) performance targets and goals for 
timely and appropriate responses by the Sec-
retary to the triggers described under subpara-
graph (A), including meetings between the Sec-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00170
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
171 
retary and the sponsor or applicant, written 
feedback, decisions by the Secretary, and other 
activities carried out as part of the development 
and review process; and 
‘‘(C) an agreement on how the plan shall be 
modified, if needed. 
‘‘(5) MILESTONES
AND
PERFORMANCE
TAR-
GETS.—The developmental milestones described in 
paragraph (4)(A) and the performance targets and 
goals described in paragraph (4)(B) shall include— 
‘‘(A) feedback from the Secretary regarding 
the data required to support the approval, clear-
ance, or licensure of the eligible countermeasure 
involved; 
‘‘(B) feedback from the Secretary regarding 
the data necessary to inform any authorization 
under section 564; 
‘‘(C) feedback from the Secretary regarding 
the data necessary to support the positioning 
and delivery of the eligible countermeasure, in-
cluding to the Strategic National Stockpile; 
‘‘(D) feedback from the Secretary regarding 
the data necessary to support the submission of 
protocols for review under section 505(b)(5)(B); 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00171
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
172 
‘‘(E) feedback from the Secretary regarding 
any gaps in scientific knowledge that will need 
resolution prior to approval, licensure, or clear-
ance of the eligible countermeasure and plans for 
conducting the necessary scientific research; 
‘‘(F) identification of the population for 
which the countermeasure sponsor or applicant 
seeks approval, licensure, or clearance and the 
population for which desired labeling would not 
be appropriate, if known; and 
‘‘(G) as necessary and appropriate, and to 
the extent practicable, a plan for demonstrating 
safety and effectiveness in pediatric populations, 
and for developing pediatric dosing, formulation, 
and administration with respect to the eligible 
countermeasure, provided that such plan would 
not delay authorization under section 564, ap-
proval, licensure, or clearance for adults. 
‘‘(6) PRIORITIZATION.— 
‘‘(A) PLANS
FOR
SECURITY
COUNTER-
MEASURES.—The Secretary shall establish regu-
latory management plans for all security coun-
termeasures for which a request is submitted 
under paragraph (3)(A). 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00172
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
173 
‘‘(B) PLANS FOR OTHER ELIGIBLE COUN-
TERMEASURES.—The Secretary shall determine 
whether resources are available to establish regu-
latory management plans for eligible counter-
measures that are not security countermeasures. 
If resources are available to establish regulatory 
management plans for eligible countermeasures 
that are not security countermeasures, and if re-
sources are not available to establish regulatory 
management plans for all eligible counter-
measures for which requests have been submitted, 
the Director of the Biomedical Advanced Re-
search and Development Authority, in consulta-
tion with the Commissioner, shall prioritize 
which eligible countermeasures may receive regu-
latory management plans.’’. 
SEC. 306. REPORT. 
Section 565 of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 360bbb–4), as amended by section 305, is 
further amended by adding at the end the following: 
‘‘(g) ANNUAL REPORT.—Not later than 180 days after 
the date of enactment of this subsection, and annually there-
after, the Secretary shall make publicly available on the 
Web site of the Food and Drug Administration a report 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00173
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
174 
that details the countermeasure development and review ac-
tivities of the Food and Drug Administration, including— 
‘‘(1) with respect to the development of new tools, 
standards, and approaches to assess and evaluate 
countermeasures— 
‘‘(A) the identification of the priorities of 
the Food and Drug Administration and the 
progress made on such priorities; and 
‘‘(B) the identification of scientific gaps 
that impede the development, approval, licensure, 
or clearance of countermeasures for populations 
with special clinical needs, including children 
and pregnant women, and the progress made on 
resolving these challenges; 
‘‘(2) with respect to countermeasures for which a 
regulatory management plan has been agreed upon 
under subsection (f), the extent to which the perform-
ance targets and goals set forth in subsection (f)(4)(B) 
and the regulatory management plan have been met, 
including, for each such countermeasure— 
‘‘(A) whether the regulatory management 
plan was completed within the required time-
frame, and the length of time taken to complete 
such plan; 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00174
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
175 
‘‘(B) whether the Secretary adhered to the 
timely and appropriate response times set forth 
in such plan; and 
‘‘(C) explanations for any failure to meet 
such performance targets and goals; 
‘‘(3) the number of regulatory teams established 
pursuant to subsection (b)(4), the number of products, 
classes of products, or technologies assigned to each 
such team, and the number of, type of, and any 
progress made as a result of consultations carried out 
under subsection (b)(4)(A); 
‘‘(4) an estimate of resources obligated to coun-
termeasure development and regulatory assessment, 
including— 
‘‘(A) Center-specific objectives and accom-
plishments; and 
‘‘(B) the number of full-time equivalent em-
ployees of the Food and Drug Administration 
who directly support the review of counter-
measures; 
‘‘(5) the number of countermeasure applications 
and submissions submitted, the number of counter-
measures approved, licensed, or cleared, the status of 
remaining submitted applications and submissions, 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00175
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
176 
and the number of each type of authorization issued 
pursuant to section 564; 
‘‘(6) the number of written requests for a regu-
latory management plan submitted under subsection 
(f)(3)(A), the number of regulatory management plans 
developed, and the number of such plans developed for 
security countermeasures; and 
‘‘(7) the number, type, and frequency of meetings 
between the Food and Drug Administration and— 
‘‘(A) sponsors of a countermeasure as de-
fined in subsection (a); or 
‘‘(B) another agency engaged in develop-
ment or management of portfolios for such coun-
termeasures, including the Centers for Disease 
Control and Prevention, the Biomedical Ad-
vanced Research and Development Authority, the 
National Institutes of Health, and the appro-
priate agencies of the Department of Defense.’’. 
SEC. 307. PEDIATRIC MEDICAL COUNTERMEASURES. 
(a) PEDIATRIC STUDIES OF DRUGS.—Section 505A of 
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a) 
is amended— 
(1) in subsection (d), by adding at the end the 
following: 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00176
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
177 
‘‘(5) CONSULTATION.—With respect to a drug 
that is a qualified countermeasure (as defined in sec-
tion 319F–1 of the Public Health Service Act), a secu-
rity countermeasure (as defined in section 319F–2 of 
the Public Health Service Act), or a qualified pan-
demic or epidemic product (as defined in section 
319F–3 of the Public Health Service Act), the Sec-
retary shall solicit input from the Assistant Secretary 
for Preparedness and Response regarding the need for 
and, from the Director of the Biomedical Advanced 
Research and Development Authority regarding the 
conduct of, pediatric studies under this section.’’; and 
(2) in subsection (n)(1), by adding at the end the 
following: 
‘‘(C) For a drug that is a qualified counter-
measure (as defined in section 319F–1 of the 
Public Health Service Act), a security counter-
measure (as defined in section 319F–2 of the 
Public Health Service Act), or a qualified pan-
demic or epidemic product (as defined in section 
319F–3 of such Act), in addition to any action 
with respect to such drug under subparagraph 
(A) or (B), the Secretary shall notify the Assist-
ant Secretary for Preparedness and Response 
and the Director of the Biomedical Advanced Re-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00177
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
178 
search and Development Authority of all pedi-
atric studies in the written request issued by the 
Commissioner of Food and Drugs.’’. 
(b) ADDITION TO PRIORITY LIST CONSIDERATIONS.— 
Section 409I of the Public Health Service Act (42 U.S.C. 
284m) is amended— 
(1) by striking subsection (a)(2) and inserting 
the following: 
‘‘(2) CONSIDERATION
OF
AVAILABLE
INFORMA-
TION.—In developing and prioritizing the list under 
paragraph (1), the Secretary— 
‘‘(A) shall consider— 
‘‘(i) therapeutic gaps in pediatrics that 
may include developmental pharmacology, 
pharmacogenetic determinants of drug re-
sponse, metabolism of drugs and biologics in 
children, and pediatric clinical trials; 
‘‘(ii) particular pediatric diseases, dis-
orders or conditions where more complete 
knowledge and testing of therapeutics, in-
cluding drugs and biologics, may be bene-
ficial in pediatric populations; and 
‘‘(iii) the adequacy of necessary infra-
structure to conduct pediatric pharma-
cological research, including research net-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00178
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
179 
works and trained pediatric investigators; 
and 
‘‘(B) may consider the availability of quali-
fied countermeasures (as defined in section 
319F–1), security countermeasures (as defined in 
section 319F–2), and qualified pandemic or epi-
demic products (as defined in section 319F–3) to 
address the needs of pediatric populations, in 
consultation with the Assistant Secretary for 
Preparedness and Response, consistent with the 
purposes of this section.’’; and 
(2) in subsection (b), by striking ‘‘subsection (a)’’ 
and inserting ‘‘paragraphs (1) and (2)(A) of sub-
section (a)’’. 
(c) ADVICE AND RECOMMENDATIONS OF THE PEDI-
ATRIC
ADVISORY
COMMITTEE
REGARDING
COUNTER-
MEASURES
FOR
PEDIATRIC
POPULATIONS.—Subsection 
(b)(2) of section 14 of the Best Pharmaceuticals for Children 
Act (42 U.S.C. 284m note) is amended— 
(1) in subparagraph (C), by striking the period 
and inserting ‘‘; and’’; and 
(2) by adding at the end the following: 
‘‘(D) the development of countermeasures 
(as defined in section 565(a) of the Federal Food, 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00179
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
180 
Drug, and Cosmetic Act) for pediatric popu-
lations.’’. 
TITLE IV—ACCELERATING MED-
ICAL COUNTERMEASURE AD-
VANCED RESEARCH AND DE-
VELOPMENT 
SEC. 401. BIOSHIELD. 
(a) PROCUREMENT OF COUNTERMEASURES.—Section 
319F–2(c) of the Public Health Service Act (42 U.S.C. 
247d–6b(c)) is amended— 
(1) in paragraph (1)(B)(i)(III)(bb), by striking 
‘‘eight years’’ and inserting ‘‘10 years’’; 
(2) in paragraph (2)(C), by striking ‘‘the des-
ignated congressional committees (as defined in para-
graph (10))’’ and inserting ‘‘the appropriate commit-
tees of Congress’’; 
(3) in paragraph (5)(B)(ii), by striking ‘‘eight 
years’’ and inserting ‘‘10 years’’; 
(4) in subparagraph (C) of paragraph (6)— 
(A) in the subparagraph heading, by strik-
ing 
‘‘DESIGNATED
CONGRESSIONAL
COMMIT-
TEES’’ and inserting ‘‘APPROPRIATE CONGRES-
SIONAL COMMITTEES’’; and 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00180
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
181 
(B) by striking ‘‘the designated congres-
sional committees’’ and inserting ‘‘the appro-
priate congressional committees’’; and 
(5) in paragraph (7)(C)— 
(A) in clause (i)(I), by inserting ‘‘including 
advanced research and development,’’ after ‘‘as 
may reasonably be required,’’; 
(B) in clause (ii)— 
(i) in subclause (III), by striking 
‘‘eight years’’ and inserting ‘‘10 years’’; and 
(ii) by striking subclause (IX) and in-
serting the following: 
‘‘(IX) 
CONTRACT
TERMS.—The 
Secretary, in any contract for procure-
ment under this section— 
‘‘(aa) may specify— 
‘‘(AA) the dosing and 
administration requirements 
for the countermeasure to be 
developed and procured; 
‘‘(BB) the amount of 
funding that will be dedi-
cated by the Secretary for 
advanced research, develop-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00181
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
182 
ment, and procurement of the 
countermeasure; and 
‘‘(CC) the specifications 
the 
countermeasure 
must 
meet to qualify for procure-
ment under a contract under 
this section; and 
‘‘(bb) shall provide a clear 
statement of defined Government 
purpose limited to uses related to 
a security countermeasure, as de-
fined in paragraph (1)(B).’’; and 
(C) by adding at the end the following: 
‘‘(viii) FLEXIBILITY.—In carrying out 
this section, the Secretary may, consistent 
with the applicable provisions of this sec-
tion, enter into contracts and other agree-
ments that are in the best interest of the 
Government in meeting identified security 
countermeasure needs, including with re-
spect to reimbursement of the cost of ad-
vanced research and development as a rea-
sonable, allowable, and allocable direct cost 
of the contract involved.’’. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00182
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
183 
(b) REAUTHORIZATION
OF
THE SPECIAL RESERVE 
FUND.—Section 319F–2 of the Public Health Service Act 
(42 U.S.C. 247d–6b) is amended— 
(1) in subsection (c)— 
(A) by striking ‘‘special reserve fund under 
paragraph (10)’’ each place it appears and in-
serting ‘‘special reserve fund as defined in sub-
section (h)’’; and 
(B) by striking paragraphs (9) and (10); 
and 
(2) by adding at the end the following: 
‘‘(g) SPECIAL RESERVE FUND.— 
‘‘(1) AUTHORIZATION OF APPROPRIATIONS.—In 
addition to amounts appropriated to the special re-
serve fund prior to the date of the enactment of this 
subsection, there is authorized to be appropriated, for 
the procurement of security countermeasures under 
subsection (c) and for carrying out section 319L (re-
lating to the Biomedical Advanced Research and De-
velopment Authority), $2,800,000,000 for the period 
of fiscal years 2014 through 2018. Amounts appro-
priated pursuant to the preceding sentence are au-
thorized to remain available until September 30, 
2019. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00183
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
184 
‘‘(2) USE OF SPECIAL RESERVE FUND FOR AD-
VANCED
RESEARCH
AND
DEVELOPMENT.—The Sec-
retary may utilize not more than 50 percent of the 
amounts authorized to be appropriated under para-
graph (1) to carry out section 319L (related to the 
Biomedical Advanced Research and Development Au-
thority). Amounts authorized to be appropriated 
under this subsection to carry out section 319L are in 
addition to amounts otherwise authorized to be ap-
propriated to carry out such section. 
‘‘(3) RESTRICTIONS
ON
USE
OF
FUNDS.— 
Amounts in the special reserve fund shall not be used 
to pay costs other than payments made by the Sec-
retary to a vendor for advanced development (under 
section 319L) or for procurement of a security coun-
termeasure under subsection (c)(7). 
‘‘(4) REPORT.—Not later than 30 days after any 
date on which the Secretary determines that the 
amount of funds in the special reserve fund available 
for procurement is less than $1,500,000,000, the Sec-
retary shall submit to the appropriate committees of 
Congress a report detailing the amount of such funds 
available for procurement and the impact such reduc-
tion in funding will have— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00184
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
185 
‘‘(A) in meeting the security countermeasure 
needs identified under this section; and 
‘‘(B) on the annual Public Health Emer-
gency Medical Countermeasures Enterprise and 
Strategy Implementation Plan (pursuant to sec-
tion 2811(d)). 
‘‘(h) DEFINITIONS.—In this section: 
‘‘(1) The term ‘advanced research and develop-
ment’ has the meaning given such term in section 
319L(a). 
‘‘(2) The term ‘special reserve fund’ means the 
‘Biodefense Countermeasures’ appropriations account, 
any appropriation made available pursuant to sec-
tion 521(a) of the Homeland Security Act of 2002, 
and any appropriation made available pursuant to 
subsection (g)(1).’’. 
SEC. 402. BIOMEDICAL ADVANCED RESEARCH AND DEVEL-
OPMENT AUTHORITY. 
(a) DUTIES.—Section 319L(c)(4) of the Public Health 
Service Act (42 U.S.C. 247d–7e(c)(4)) is amended— 
(1) in subparagraph (B)(iii), by inserting 
‘‘(which may include advanced research and develop-
ment for purposes of fulfilling requirements under the 
Federal Food, Drug, and Cosmetic Act or section 351 
of this Act)’’ after ‘‘development’’; and 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00185
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
186 
(2) in subparagraph (D)(iii), by striking ‘‘and 
vaccine manufacturing technologies’’ and inserting 
‘‘vaccine-manufacturing 
technologies, 
dose-sparing 
technologies, 
efficacy-increasing 
technologies, 
and 
platform technologies’’. 
(b) TRANSACTION AUTHORITIES.—Section 319L(c)(5) 
of the Public Health Service Act (42 U.S.C. 247d–7e(c)(5)) 
is amended by adding at the end the following: 
‘‘(G) GOVERNMENT
PURPOSE.—In award-
ing contracts, grants, and cooperative agreements 
under this section, the Secretary shall provide a 
clear statement of defined Government purpose 
related to activities included in subsection 
(a)(6)(B) for a qualified countermeasure or 
qualified pandemic or epidemic product.’’. 
(c) FUND.—Paragraph (2) of section 319L(d) of the 
Public Health Service Act (42 U.S.C. 247d–7e(d)(2)) is 
amended to read as follows: 
‘‘(2) FUNDING.—To carry out the purposes of 
this section, there is authorized to be appropriated to 
the Fund $415,000,000 for each of fiscal years 2014 
through 2018, such amounts to remain available until 
expended.’’. 
(d) CONTINUED INAPPLICABILITY OF CERTAIN PROVI-
SIONS.—Section 319L(e)(1)(C) of the Public Health Service 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00186
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
187 
Act (42 U.S.C. 247d–7e(e)(1)(C)) is amended by striking 
‘‘7 years’’ and inserting ‘‘12 years’’. 
(e) EXTENSION
OF
LIMITED
ANTITRUST
EXEMP-
TION.— 
(1) IN GENERAL.—Section 405(b) of the Pan-
demic and All-Hazards Preparedness Act (42 U.S.C. 
247d–6a note) is amended by striking ‘‘6-year’’ and 
inserting ‘‘12-year’’. 
(2) EFFECTIVE DATE.—This subsection shall take 
effect as if enacted on December 17, 2012. 
(f) INDEPENDENT EVALUATION.—Section 319L of the 
Public Health Service Act (42 U.S.C. 247d–7e) is amended 
by adding at the end the following: 
‘‘(f) INDEPENDENT EVALUATION.— 
‘‘(1) IN
GENERAL.—Not later than 180 days 
after the date of enactment of this subsection, the 
Comptroller General of the United States shall con-
duct an independent evaluation of the activities car-
ried out to facilitate flexible manufacturing capacity 
pursuant to this section. 
‘‘(2) REPORT.—Not later than 1 year after the 
date of enactment of this subsection, the Comptroller 
General of the United States shall submit to the ap-
propriate committees of Congress a report concerning 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00187
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
188 
the results of the evaluation conducted under para-
graph (1). Such report shall review and assess— 
‘‘(A) the extent to which flexible manufac-
turing capacity under this section is dedicated to 
chemical, biological, radiological, and nuclear 
threats; 
‘‘(B) the activities supported by flexible 
manufacturing initiatives; and 
‘‘(C) the ability of flexible manufacturing 
activities carried out under this section to— 
‘‘(i) secure and leverage leading tech-
nical expertise with respect to counter-
measure advanced research, development, 
and manufacturing processes; and 
‘‘(ii) meet the surge manufacturing ca-
pacity needs presented by novel and emerg-
ing threats, including chemical, biological, 
radiological, and nuclear agents.’’. 
(g) DEFINITIONS.— 
(1) 
QUALIFIED
COUNTERMEASURE.—Section 
319F–1(a)(2)(A) of the Public Health Service Act (42 
U.S.C. 247d–6a(a)(2)(A)) is amended— 
(A) in the matter preceding clause (i), by 
striking ‘‘to—’’ and inserting ‘‘—’’; 
(B) in clause (i)— 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00188
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
189 
(i) by striking ‘‘diagnose’’ and insert-
ing ‘‘to diagnose’’; and 
(ii) by striking ‘‘; or’’ and inserting a 
semicolon; 
(C) in clause (ii)— 
(i) by striking ‘‘diagnose’’ and insert-
ing ‘‘to diagnose’’; and 
(ii) by striking the period at the end 
and inserting ‘‘; or’’; and 
(D) by adding at the end the following: 
‘‘(iii) is a product or technology in-
tended to enhance the use or effect of a drug, 
biological product, or device described in 
clause (i) or (ii).’’. 
(2) QUALIFIED PANDEMIC OR EPIDEMIC PROD-
UCT.—Section 319F–3(i)(7)(A) of the Public Health 
Service Act (42 U.S.C. 247d–6d(i)(7)(A)) is amend-
ed— 
(A) in clause (i)(II), by striking ‘‘; or’’ and 
inserting ‘‘;’’; 
(B) in clause (ii), by striking ‘‘; and’’ and 
inserting ‘‘; or’’; and 
(C) by adding at the end the following: 
‘‘(iii) a product or technology intended 
to enhance the use or effect of a drug, bio-
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00189
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
190 
logical product, or device described in clause 
(i) or (ii); and’’. 
(3) TECHNICAL
AMENDMENTS.—Section 319F– 
3(i) of the Public Health Service Act (42 U.S.C. 
247d–6d(i)) is amended— 
(A) in paragraph (1)(C), by inserting ‘‘, 
564A, or 564B’’ after ‘‘564’’; and 
(B) in paragraph (7)(B)(iii), by inserting 
‘‘, 564A, or 564B’’ after ‘‘564’’. 
SEC. 403. STRATEGIC NATIONAL STOCKPILE. 
Section 319F–2 of the Public Health Service Act (42 
U.S.C. 247d–6b) is amended— 
(1) in subsection (a)— 
(A) in paragraph (1)— 
(i) by inserting ‘‘consistent with sec-
tion 2811’’ before ‘‘by the Secretary to be 
appropriate’’; and 
(ii) by inserting before the period at 
the end of the second sentence the following: 
‘‘and shall submit such review annually to 
the appropriate congressional committees of 
jurisdiction to the extent that disclosure of 
such information does not compromise na-
tional security’’; and 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00190
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
191 
(B) in paragraph (2)(D), by inserting be-
fore the semicolon at the end the following: ‘‘and 
that the potential depletion of countermeasures 
currently in the stockpile is identified and ap-
propriately addressed, including through nec-
essary replenishment’’; and 
(2) 
in 
subsection 
(f)(1), 
by 
striking 
‘‘$640,000,000 for fiscal year 2002, and such sums as 
may be necessary for each of fiscal years 2003 through 
2006. Such authorization is in addition to amounts 
in the special reserve fund referred to in subsection 
(c)(10)(A).’’ and inserting ‘‘$533,800,000 for each of 
fiscal years 2014 through 2018. Such authorization is 
in addition to amounts in the special reserve fund re-
ferred to in subsection (h).’’. 
SEC. 404. NATIONAL BIODEFENSE SCIENCE BOARD. 
Section 319M(a) of the Public Health Service Act (42 
U.S.C. 247d–f(a)) is amended— 
(1) in paragraph (2)— 
(A) in subparagraph (D)— 
(i) in clause (i), by striking ‘‘and’’ at 
the end; 
(ii) in clause (ii), by striking the pe-
riod and inserting a semicolon; and 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00191
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
192 
(iii) by adding at the end the fol-
lowing: 
‘‘(iii) one such member shall be an in-
dividual with pediatric subject matter ex-
pertise; and 
‘‘(iv) one such member shall be a State, 
tribal, territorial, or local public health offi-
cial.’’; and 
(B) by adding at the end the following flush 
sentence: 
‘‘Nothing in this paragraph shall preclude a member 
of the Board from satisfying two or more of the re-
quirements described in subparagraph (D).’’; and 
(2) in paragraph (5)— 
(A) in subparagraph (B), by striking ‘‘and’’ 
at the end; 
(B) in subparagraph (C), by striking the 
period and inserting ‘‘; and’’; and 
(C) by adding at the end the following: 
‘‘(D) provide any recommendation, finding, 
or report provided to the Secretary under this 
paragraph to the appropriate committees of Con-
gress.’’. 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00192
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00193
Fmt 6652
Sfmt 6203
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS
Calendar No. 14 
113TH CONGRESS 
1ST SESSION 
H. R. 307 
AN ACT 
To reauthorize certain programs under the Public 
Health Service Act and the Federal Food, Drug, 
and Cosmetic Act with respect to public health 
security and all-hazards preparedness and re-
sponse, and for other purposes. 
FEBRUARY 14, 2013 
Reported with an amendment 
VerDate Mar 15 2010 
22:31 Feb 14, 2013
Jkt 029200
PO 00000
Frm 00194
Fmt 6651
Sfmt 6651
E:\BILLS\H307.RS
H307
srobinson on DSK4SPTVN1PROD with BILLS